Howe & Rusling Inc Seagen Inc. Transaction History

Howe & Rusling Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$191.51 - $216.16 $27,194 - $30,694	-142 Reduced 7.42%	1,772 $375,000
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $160,244 - $176,137	-854 Reduced 30.85%	1,914 $368,000
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $2.03 Million - $3.23 Million	-15,903 Reduced 85.17%	2,768 $560,000
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $517,601 - $613,739	-4,410 Reduced 19.11%	18,671 $2.4 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $12,444 - $16,570	-92 Reduced 0.4%	23,081 $3.16 Million

Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $51,140 - $84,285	470 Added 2.07%	23,173 $4.1 Million
Q1 2022 May 10, 2022	BUY	$119.61 - $157.85 $1.16 Million - $1.53 Million	9,665 Added 74.13%	22,703 $3.27 Million
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $105,786 - $141,618	-742 Reduced 5.38%	13,038 $2.02 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $1.96 Million - $2.33 Million	13,746 Added 40429.41%	13,780 $2.34 Million
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $4,592 - $5,477	34 New	34 $5,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Howe & Rusling Inc, based on Form 13F filings with the SEC.

Stay updated on Howe & Rusling Inc with notifications on news.